PARIS, May 11 /PRNewswire-FirstCall/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, announces today that Frederic Paques, PhD, Chief Scientific Officer, has been invited to present Cellectis' approaches on vectors for meganucleases and genome surgery at the 13th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting to be held at the Marriott Wardman Park Hotel in Washington, USA, on May 19-22, 2010.
Targeted approaches have emerged today as an alternative to current random insertion strategies for gene therapy. Meganucleases, the most specific endonucleases, represent ideal tools for targeted genome editing, or genome surgery. They can induce up to 20% of gene insertion into chosen human genes. The entry of meganucleases into different cell types can be achieved by various means, including viral and non-viral vectorization.
Dr Paques will discuss "Meganucleases and Viral Vectors: Alternative or Complementary Approaches" on May 22, 2010, at 8:30AM, during an oral session on Special Considerations with Using Viral Vectors for Gene Modification of Stem Cells.
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools - meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.
To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company
Copyright©2010 PR Newswire.
All rights reserved